Market Overview
Monoclonal antibodies (mAbs) are antibodies produced by a single clone of a B lymphocyte and are therefore identical regarding their physicochemical and biological properties. To make a monoclonal antibody, researchers first have to identify the right antigen to attack. Finding the right antigens for cancer cells is not always easy, and so far mAbs have proven to be more useful against some cancers than others. For more than 20 years, mAbs have been important in treating many types of cancer. The first therapeutic mAbs, muromonab-CD3 (Orthoclone OKT3), was approved by the US FDA in 1986 and comprises a murine mAb against T cell-expressed CD3 that functions as an immunosuppressant for the treatment of acute transplant rejection.
The global Cancer Monoclonal Antibodies Market size was worth $40,767.4 million in 2019 and is forecasted to reach $77,086.9 million by 2026, at a CAGR of 9.5% during the forecast period.
Market Dynamics
Drivers
-
Rising Incidence/Prevalence cases of cancer
-
Advancements in Monoclonal Antibodies
-
Increasing demand for Monoclonal Antibodies
Restraints
-
High costs of Mab-indication combinations treatment
-
Limitations & risks of side effects from Mab Therapy
-
Mono-specificity
Market Segmentation
The Humanized Market is valued at USD$7,395.7 Mn in 2019 and is estimated to grow at a CAGR of 9.4% over the forecast period to reach a USD$13,886.8 Mn by 2026. The Humanized segment holds 18.1% of the market share in 2019, and is expected to be 18.0% by 2026, for the Global Cancer Monoclonal Antibodies Market.
Humanized monoclonal antibodies (IgM, IgG or IgA) generate lower levels of Anti drug antibodies (ADA’s) compared to chimeric monoclonal antibodies, although the incidence of ADAs is not eliminated. The development of humanized mAbs is based on different parameters. The design and nature of preclinical and non-clinical studies depends on numerous factors including: target, route of administration, species, indication, pharmacology, pharmacokinetics, and clinical plan.
Geographical Analysis
North America occupied the highest market share of about 44.4% in 2019 which is expected to increase to 45.5% by 2026.
The North America segment of Cancer Monoclonal Antibodies market is valued at US$18,112.0 Million in 2019 and is estimated to grow at a CAGR of 9.9% over the forecast period to reach US$35,062.2 Million by 2026.
The U.S holds 73.1% of market share in 2019, and is expected to increase to 73.7% by 2026, for the North America Cancer Monoclonal Antibodies market. The collective revenue of Cancer Monoclonal Antibodies market by North America is expected to generate USD 1,99,614.8 Mn from 2019-2026. The Americas (North and South) have 13.3% of the global population of cancer cases and account for 21.0% of incidence and 14.4% of mortality worldwide.
North America is expected to dominate the overall market, owing to the well-established healthcare infrastructure and availability of advanced healthcare facilities. The increasing number of cancer cases, in the United States , is another important factor, which is expected to increase the growth of the market. Technological advancement is one of the important ongoing trends in the Cancer Monoclonal Antibodies market. The researchers and manufacturers are focusing on the development of highly advanced antibodies, which is expected to increase the growth of the overall market. There is an enhanced availability of skilled personnel and healthcare professionals, along with the well-established healthcare infrastructure. This is expected to increase the number of cancer treatment cases.
Competitive Landscape
Today a lot of companies are focusing on the development of new drugs for the treatment of cancer as this area has a high unmet need. New Product Launches, partnerships, and acquisition are the major strategies adopted by the leading companies in the industry. Companies are today undergoing strategic collaborations in order to enhance their capability for clinical trials with a number of top players are biotech companies. Efficient distribution networks, product differentiation and supply competency play a major role in determining the market position of such players. Majority of these players are focusing on expanding their distribution network as well as expanding presence in the Asia Pacific, Latin America and the Middle East regions due to rising development of advanced products for various implants.
About Us:
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com